Amino-Acid Metabolism Disorders – Cannabis Research

Amino-Acid Metabolism Disorders Research Dashboard


Primary Studies


Related Studies


Total Studies

Clinical Studies


Clinical Meta-analyses


Double-blind human trials


Clinical human trials

Pre-Clinical Studies




Animal studies


Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 3 studies associated with Amino-Acid Metabolism Disorders.

Here is a small sampling of Amino-Acid Metabolism Disorders studies by title:

Components of the Amino-Acid Metabolism Disorders Research Dashboard

  • Dosing information available for Amino-Acid Metabolism Disorders
  • Chemotype guidance for treating Amino-Acid Metabolism Disorders with cannabis
  • Synopsis of cannabis research for Amino-Acid Metabolism Disorders
  • Individual study details for Amino-Acid Metabolism Disorders

Ready to become a subscriber? Go to our PRICING page.

Select New Condition

Search By Keyword

Filter Condition

Members can filter by the following criteria:

  • Study Type
  • Chemotype
  • Cannabinoids & Endocannabinoids
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Amino-Acid Metabolism Disorders

Description of Amino-Acid Metabolism Disorders

There is a wide variety of amino-acid metabolism disorders, also called inborn errors of metabolism. Many of these are screened for during pregnancy and at birth. Genetic mutations (usually autosomal recessive) in metabolic pathways cause systemic issues with processing of nutrients and excess buildup of substrates, intermediate, or final cellular waste products. These cause downstream effects in physiology that lead to identifiable patterns of health issues in multiple organ systems and in behavior/intellect/development (e.g. ocular, musculoskeletal, hepatorenal, cerebral, cardiac, etc).

One example of an amino-acid metabolism disorder is Lowe syndrome, a rare genetic disorder that affects the amino acid metabolism and is seen almost exclusively in boys. Lowe's severely affects quality of life but most commonly the eyes, brain, muscles and kidneys of affected boys. Many male children with Lowe's are born with the kind of cognitive impairment, kidney problems, eye conditions (glaucoma, cataracts, blindness), muscular (poor tone) and skeletal (scoliosis, soft bones that easily fracture) problems that we are more used to seeing in some very unhealthy seniors.

Disease Classification

Condition: Amino-Acid Metabolism Disorders
Disease Family:
Organ System: Endocrine System, Nervous System
ICD-10 Chapter: Endocrine, Nutritional and Metabolic Diseases
ICD-10 Code: E72

Amino-Acid Metabolism Disorders Symptoms:

Drowsiness, fussiness, little appetite, throwing up, being restless or having trouble being still or quiet, changes in muscle tone, muscle weakness, coordination or balance problems, dry hair that breaks easily, learning problems, slow growth, small head, unclear speech, breathing problems, high levels of ammonia in the blood can cause intense headache especially after a high-protein meal, loss of consciousness (passing out), low body temperature, being tall and thin with long legs and arms, or long, curved fingers, chest deformities (abnormal shape), dislocation of the eye lens, failure to thrive (slow weight gain and growth), knock knees, pale hair and skin, problems with movement, redness across the cheeks, behavior and emotional problems, intellectual and developmental disabilities, high-pitched cry, trouble feeding, urine that smells like maple syrup, weight loss, bruising or bleeding, especially nosebleeds, diarrhea, bloody stools, fast heartbeat, jaundice, skin or urine that smells like cabbage, slow weight gain and growth, swollen belly or legs, trouble walking, increased tear production, sensitivity to light (photophobia), eye redness, skin lesions on the hands and feet, hyperactivity

Also known as:

Lowe Syndrome, Oculocerebrorenal syndrome, phenylketonuria, Cystinuria, Cystinosis, Hartnup disease, Cystathioninuria, Cystathioninuria, Hypermethioninemia, Homocystinuria, Sulfite oxidase deficiency, Argininaemia, Argininosuccinic aciduria, Citrullinaemia, Hyperammonemia, Glutaric aciduria, Glutaric aciduria, Disorders of amino-acid transport.

Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example. 
  • THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), beta-blockers (e.g. propranolol), bronchodilators (e.g. theophylline), or bloodthinners (e.g. warfarin).  Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
  • Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

CBD Interaction with Pharmaceutical Drugs

  • CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
  • Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg
  • THC low dose:  0.5 mg to 5 mg
  • THC medium dose:  6 mg to 20 mg
  • THC high dose:  21 mg to 50+ mg

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg
  • CBD medium dose: 20 mg to 99 mg
  • CBD high dose:  100 mg to 800+ mg (upper limits tested ~1,500mg)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.